Pituitary Dwarf Treatment Global Market Report 2024

The primary categories of pituitary dwarfism treatment include pituitary dwarfism type I, pituitary dwarfism type II, pituitary dwarfism type III, pituitary dwarfism type IV, and others. Pituitary dwarfism type I, also known as isolated growth hormone deficiency type I, is a medical condition characterized by insufficient production of growth hormone (GH) from the pituitary gland. Various treatment options are available, including surgery, additional therapies, drugs, and others. These treatments are administered through different routes, including parenteral and others, and are utilized by various end-users, such as hospitals, homecare, specialty clinics, and others.

This report provides pituitary dwarf treatment market statistics, including pituitary dwarf treatment industry global market size, regional shares, competitors with a pituitary dwarf treatment market share, detailed pituitary dwarf treatment market segments, market trends and opportunities and any further data you may need to thrive in the pituitary dwarf treatment industry. This pituitary dwarf treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global pituitary dwarf treatment market has grown rapidly in recent years. It will grow from $4.76 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increasing demand for pituitary dwarf treatment drugs, growing prevalence of pituitary dwarfism, awareness of pituitary dwarfism.

The global pituitary dwarf treatment market is expected to see rapid growth in the next few years. It will grow to $9.4 billion in 2028 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to rising geriatric population, rising healthcare spending, growth hormone treatment, growing demand for prescription treatments for pituitary dwarfism
. Major trends in the forecast period include advancements in medical research, drug approvals, advancements in drug delivery systems, innovative growth hormone formulations, genetic testing.

The anticipated increase in the prevalence of growth hormone deficiency is set to be a significant driver for the growth of the pituitary dwarf treatment market in the coming years. Growth hormone deficiency (GHD) is a medical condition characterized by inadequate production or secretion of growth hormone (GH) by the pituitary gland. Pituitary dwarf treatment encompasses hormonal therapies aimed at enhancing growth, bone health, metabolic regulation, and overall quality of life for individuals affected by dwarfism and growth hormone deficiency. For example, as of January 2021, data from the European Medicines Agency (EMA), a decentralized agency based in the UK, indicated that approximately 6,000 adults in the United States are estimated to be diagnosed with adult growth hormone deficiency (AGHD) each year. Hence, the increasing prevalence of growth hormone deficiency is a key factor driving the expansion of the pituitary dwarf treatment market.

The expected increase in the prevalence of hormonal disorders is poised to be a significant driver for the future growth of the pituitary dwarf treatment market. Hormonal disorders encompass medical conditions characterized by irregularities in the functioning of the endocrine system. Situated at the base of the brain, the pituitary gland assumes a central role in regulating the production and release of hormones, including growth hormone (GH). For instance, as of 2021, data from the National Center for Biotechnology Information, a U.S.-based national charity, indicated that the prevalence of hormonal disorders stands at approximately 45 cases per 100,000 individuals, with an annual incidence rate of 4 cases per 100,000 inhabitants. Consequently, the increasing occurrence of hormonal disorders is the driving force behind the expansion of the market for pituitary dwarf treatment.

The substantial costs associated with medications represent a significant obstacle that impedes the growth of the pituitary dwarf treatment market. These high costs restrict patient access to crucial treatments, creating financial barriers that can deter both patients and insurance providers, consequently limiting the coverage of treatment for many individuals. For example, as indicated in a June 2021 article published in the National Library of Medicine, a U.S.-based medical library, Japan has implemented a tiered governmental cost support system for recombinant human growth hormone (rhGH) therapy, a treatment option for pituitary dwarfism. This highlights the considerable expenses associated with pituitary dwarf treatment. Therefore, the elevated cost of pituitary dwarf treatment serves as a hindrance to the growth of the market in this field.

The leading companies within the pituitary dwarf treatment market are actively directing their efforts toward the development of innovative products to maintain and advance their standing within the market. For example, in April 2023, Novo Nordisk A/S, a pharmaceutical company headquartered in Denmark, launched Sogroya (somapacitan-beco) injections in 5 mg, 10 mg, and 15 mg variants, following approval from the U.S. Food and Drug Administration (FDA). This novel offering is designed to address growth deficiencies in children aged 2.5 years and older, stemming from insufficient endogenous growth hormone secretion. With this newly added indication, Sogroya now stands as the sole once-weekly growth hormone (GH) medication available for both children and adults.

In September 2021, Biocorp Production SA, a medical and drug delivery device manufacturer headquartered in France, entered into a strategic partnership with Merck KGaA, a pharmaceutical company based in Germany. The core objective of this collaboration is to jointly develop and market a specialized version of the Mallya device tailored for use in the Human Growth Hormone domain. Merck KGaA is renowned for its pharmaceutical endeavors in the realm of growth hormone deficiency treatments.

Major players in the pituitary dwarf treatment market are Pfizer Inc., Merck and Co Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, H. Lundbeck A/S, Mylan N.V., Teva Pharmaceutical Industries Ltd., Ipsen Pharma S.A., Genentech Inc., Apotex Inc., Cipla Limited, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co Ltd., Amneal Pharmaceuticals LLC., BioMarin Pharmaceutical Inc., Biopartners GmbH, Elekta AB, Xiamen Amoytop Biotech Co Ltd., Lifetech Labs, Alnylam Pharmaceuticals Inc., GeneScience Pharmaceuticals Co Ltd., Armata Pharmaceuticals Inc., Alkermes Plc.

North America was the largest region in the pituitary dwarf treatment market in 2023. The regions covered in pituitary dwarf treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pituitary dwarf treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pituitary dwarf treatment market consists of revenues earned by entities by providing hormone replacement therapy (HRT), combined hormone therapy, synthetic human growth hormone injections and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pituitary dwarf treatment market also includes sales of somatropin, bromocriptine and octreotide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.